The effect of propofol and sevoflurane on cancer cell, natural killer cell, and cytotoxic T lymphocyte function in patients undergoing breast cancer surgery: an in vitro analysis

[1]  B. Lu,et al.  Immune Modulation by Volatile Anesthetics , 2016, Anesthesiology.

[2]  R. Eckenhoff,et al.  Mechanisms of the Immunological Effects of Volatile Anesthetics: A Review , 2016, Anesthesia and analgesia.

[3]  G. Strichartz,et al.  Cancer surgery: how may anesthesia influence outcome? , 2015, Journal of clinical anesthesia.

[4]  J. Liu,et al.  Impact of isoflurane on malignant capability of ovarian cancer in vitro. , 2015, British journal of anaesthesia.

[5]  R. Brown,et al.  Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination , 2014, British Journal of Cancer.

[6]  K. Rooney,et al.  IV. Increased kidney donation rates in the Scottish NHS: a historical problem being successfully addressed. , 2014, British journal of anaesthesia.

[7]  D. Buggy,et al.  Effect of anaesthetic technique on the natural killer cell anti-tumour activity of serum from women undergoing breast cancer surgery: a pilot study. , 2014, British journal of anaesthesia.

[8]  H. Gallagher,et al.  Differential effects of serum from patients administered distinct anaesthetic techniques on apoptosis in breast cancer cells in vitro: a pilot study. , 2014, British journal of anaesthesia.

[9]  H. Hemmings,et al.  Special issue on anaesthesia and cancer. , 2014, British journal of anaesthesia.

[10]  K. Liu,et al.  Effects of Different General Anaesthetic Techniques on Immune Responses in Patients Undergoing Surgery for Tongue Cancer , 2014, Anaesthesia and intensive care.

[11]  S. Mondello,et al.  Anesthetic Techniques and Cancer Recurrence after Surgery , 2014, TheScientificWorldJournal.

[12]  P. Doran,et al.  Effects of sevoflurane on breast cancer cell function in vitro. , 2013, Anticancer research.

[13]  D. Ma,et al.  Isoflurane, a Commonly Used Volatile Anesthetic, Enhances Renal Cancer Growth and Malignant Potential via the Hypoxia-inducible Factor Cellular Signaling Pathway In Vitro , 2013, Anesthesiology.

[14]  G. Salles,et al.  Monitoring NK cell activity in patients with hematological malignancies , 2013, Oncoimmunology.

[15]  D. Lambert,et al.  Can anesthetic techniques or drugs affect cancer recurrence in patients undergoing cancer surgery? , 2013, Journal of Anesthesia.

[16]  B. Beck-Schimmer,et al.  Volatile Anesthetics Reduce Invasion of Colorectal Cancer Cells through Down-regulation of Matrix Metalloproteinase-9 , 2012, Anesthesiology.

[17]  D. Ma,et al.  Cancer recurrence after surgery: Direct and indirect effects of anesthetic agents * , 2012, International journal of cancer.

[18]  L. Aguilar,et al.  Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development , 2011, Journal of cellular biochemistry.

[19]  F. Granath,et al.  Malignant Disease Within 5 Years After Surgery in Relation to Duration of Sevoflurane Anesthesia and Time with Bispectral Index Under 45 , 2011, Anesthesia and analgesia.

[20]  J. Bengtson,et al.  Inflammatory response in patients undergoing colorectal cancer surgery: the effect of two different anesthetic techniques. , 2011, Minerva anestesiologica.

[21]  P. Doran,et al.  Effect of Anesthetic Technique on Serum Vascular Endothelial Growth Factor C and Transforming Growth Factor &bgr; in Women Undergoing Anesthesia and Surgery for Breast Cancer , 2010, Anesthesiology.

[22]  G. Snyder,et al.  Effect of anaesthetic technique and other perioperative factors on cancer recurrence. , 2010, British journal of anaesthesia.

[23]  E. Mascha,et al.  Anesthetic Technique and the Cytokine and Matrix Metalloproteinase Response to Primary Breast Cancer Surgery , 2010, Regional Anesthesia & Pain Medicine.

[24]  L. Lanier,et al.  TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. , 2010, Neuro-oncology.

[25]  Zlatko Trajanoski,et al.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Masato Kato,et al.  Anesthetics, immune cells, and immune responses , 2008, Journal of Anesthesia.

[27]  K. Shingu,et al.  Enhancement of Antitumor Immunity after Propofol Treatment in Mice , 2007, Immunopharmacology and immunotoxicology.

[28]  S. Ben-Eliyahu,et al.  Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches. , 2006, Breast disease.

[29]  P. Basse,et al.  Antitumor activity of NK cells , 2006, Immunologic research.

[30]  G. Shakhar,et al.  Suppression of Natural Killer Cell Activity and Promotion of Tumor Metastasis by Ketamine, Thiopental, and Halothane, but Not by Propofol: Mediating Mechanisms and Prophylactic Measures , 2003, Anesthesia and analgesia.

[31]  J. Chang-Claude,et al.  A Transforming Growth Factorβ1 Signal Peptide Variant Increases Secretion in Vitro and Is Associated with Increased Incidence of Invasive Breast Cancer , 2003 .

[32]  J. Chang-Claude,et al.  A transforming growth factorbeta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. , 2003, Cancer research.

[33]  P. Sacerdote,et al.  Experimental evidence for immunomodulatory effects of opioids. , 2003, Advances in experimental medicine and biology.

[34]  A. Mammoto,et al.  Intravenous anesthetic, propofol inhibits invasion of cancer cells. , 2002, Cancer letters.

[35]  T. Horinouchi,et al.  Inhalation Anesthetics Induce Apoptosis in Normal Peripheral Lymphocytes In Vitro , 2001, Anesthesiology.

[36]  Carlos L Arteaga,et al.  Transforming growth factor-β and breast cancer: Tumor promoting effects of transforming growth factor-β , 2000, Breast Cancer Research.

[37]  D. Scheinichen,et al.  Remifentanil, fentanyl, and alfentanil have no influence on the respiratory burst of human neutrophils in vitro , 1998, Acta anaesthesiologica Scandinavica.

[38]  R. Vile,et al.  Generation of an anti‐tumour immune response in a non‐immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1‐like profile of intratumoural cytokine expression , 1997, International journal of cancer.

[39]  S L Shafer,et al.  Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Remifentanil: I. Model Development , 1997, Anesthesiology.

[40]  Thomas W. Schnider,et al.  Pharmacokinetics and Pharmacodynamics of Remifentanil: II. Model Application , 1997, Anesthesiology.

[41]  Thomas W. Schnider,et al.  Pharmacokinetics and Pharmacodynamics of Remifentanil , 1997 .

[42]  M. Yokoyama,et al.  Suppressive effects of volatile anesthetics on cytokine release in human peripheral blood mononuclear cells. , 1995, International journal of immunopharmacology.

[43]  N. Morton,et al.  Pharmacokinetic model driven infusion of propofol in children. , 1991, British journal of anaesthesia.

[44]  S. Segal,et al.  Anesthetic drugs accelerate the progression of postoperative metastases of mouse tumors. , 1981, The Journal of clinical investigation.

[45]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.